Trials / Unknown
UnknownNCT05047848
Clinical Study of Chidamide Combined With Fulvestrant in the Treatment of Hormone Receptor-positive Advanced Breast Cancer
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 82 (estimated)
- Sponsor
- Liaoning Cancer Hospital & Institute · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Open-label study of chidamide in combination with fulvestrant for the treatment of postmenopausal women with hormone receptor positive, Her2 negative, advanced breast cancer who have received no or only one line of endocrine therapy for advanced breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Chidamide | chidamide 30mg orally，Biw |
| DRUG | Fulvestrant | Fulvestrant 500mg i.m. injections every 28 days (Cycle n Day 1) with 1 additional dose on Day 15 of Cycle 1 |
Timeline
- Start date
- 2021-08-18
- Primary completion
- 2022-06-18
- Completion
- 2023-09-18
- First posted
- 2021-09-17
- Last updated
- 2021-09-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05047848. Inclusion in this directory is not an endorsement.